US Patent

US9126947 — Substituted pyridazine carboxamide compounds

Composition of Matter · Assigned to Xcovery Holding Co LLC · Expires 2031-11-29 · 6y remaining

Vulnerability score 23/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects new pyridazine derivatives with unexpected properties as inhibitors of protein kinases, particularly against ALK.

USPTO Abstract

The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against ALK and are useful in treating disorders related to abnormal protein kinase activities such as cancer, neurological and psychiatric diseases.

Drugs covered by this patent

Patent Metadata

Patent number
US9126947
Jurisdiction
US
Classification
Composition of Matter
Expires
2031-11-29
Drug substance claim
Yes
Drug product claim
No
Assignee
Xcovery Holding Co LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.